Victor Tenenbaum, DO
Family Medicine · New York, NYNPI 1023185618
Payments from drug & device makers
Across 205 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$889
- AstraZeneca$831
- Novo Nordisk$384
- Merck$377
- Lilly USA, LLC$358
- Gilead$292
- plus $2K from 16 others
What the payments were for
- Food & beverage$4,692100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 37 | $889 |
| AstraZeneca | 38 | $831 |
| Novo Nordisk | 16 | $384 |
| Merck | 20 | $377 |
| Lilly USA, LLC | 15 | $358 |
| Gilead | 11 | $292 |
| GSK | 14 | $274 |
| Amarin Pharma, Inc. | 9 | $217 |
| Boehringer Ingelheim | 7 | $213 |
| Esperion Therapeutics, Inc. | 8 | $175 |
| Amgen | 7 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $125 |
| Corcept Therapeutics | 3 | $80 |
| Pfizer | 3 | $72 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| AbbVie | 2 | $41 |
| Novartis | 2 | $41 |
| Exact Sciences | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Arbor Pharmaceuticals, Inc. | 1 | $27 |
| Viiv Healthcare Company | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
How this compares
$4,714 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $81,277 |
| FarxigaDapagliflozin Propanediol | 61 | $80,489 |
| JardianceEmpagliflozin | 57 | $74,133 |
| EliquisApixaban | 69 | $72,534 |
| MounjaroTirzepatide | 63 | $67,400 |
| JanuviaSitagliptin Phosphate | 45 | $52,264 |
| TrulicityDulaglutide | 27 | $47,125 |
| KerendiaFinerenone | 29 | $41,008 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $34,168 |
| TradjentaLinagliptin | 28 | $31,354 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $8,760 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,095 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 19 | $5,708 |
| Atorvastatin Calcium | 474 | $4,997 |
| Novolog FlexpenInsulin Aspart | 13 | $4,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $358 | $114,52590 claims |
| Boehringer IngelheimJardiance, Tradjenta | $213 | $105,48885 claims |
| MerckJanuvia, Janumet | $377 | $86,43270 claims |
| Novo NordiskOzempic | $384 | $81,27770 claims |
| AstraZenecaFarxiga | $831 | $80,48961 claims |
| PfizerEliquis | $72 | $72,53469 claims |
| BayerKerendia | $889 | $41,00829 claims |
| GSKBreo Ellipta | $274 | $7,09511 claims |
| AbbVieSynthroid | $41 | $1,86520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Matthew PabisNew York$222K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Punyadech PhotangthamNew York$107K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.